EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

Jinghan Zhu iD, Yixiao Xiong, Yuxin Zhang, Huifang Liang iD, Kun Cheng, Yuanxiang Lu, Guangzhen Cai, Yang Wu, Yunhui Fan, Xiaoping Chen, Hong Zhu, Zeyang Ding und 1 weitere

Cancer Communications · 2025-08 · 45 (8) · 1038-1071

DOI: 10.1002/cac2.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 29.05.2025. Verfasst von Jinghan Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Cholangiocarcinoma, Proto-Oncogene Proteins c-akt, Bile Duct Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, China National Postdoctoral Program for Innovative Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cancer. Ferroptosis is a crucial process that affects cancer cell survival and therapy resistance. Although AKT hyperactivation is prevalent in numerous cancers, including ICC, its role in ferroptosis resistance remains unclear. This study explored whether targeting ferroptosis can enhance CIT response rates, specifically in ICC patients with AKT hyperactivation.

Methods

In vivo metabolic CRISPR screening in a Kras G12D /Tp53 −/− ICC mouse model was used to identify primary regulators of ferroptosis during CIT (gemcitabine, cisplatin, and anti‐mouse programmed cell death 1 ligand 1). Phosphoenolpyruvate carboxykinase 1 (PCK1) was assessed for its role in ferroptosis and treatment resistance in preclinical models under AKT activation levels. Molecular and biochemical techniques were used to explore PCK1‐related resistance mechanisms in AKT‐hyperactivated ICC.

Results

Under AKT hyperactivation condition, phosphorylated PCK1 (pPCK1) promoted metabolic reprogramming, enhancing ubiquinol and menaquinone‐4 synthesis through the mevalonate (MVA) pathway. This cascade was mediated by the pPCK1‐pLDHA‐SPRINGlac axis. Inhibiting PCK1 phosphorylation or using simvastatin significantly augmented CIT efficacy in preclinical models. Clinical data further indicated that phosphorylated AKT (pAKT)‐pPCK1 levels might serve as a biomarker to predict CIT response in ICC.

Conclusion

This study identified the pAKT‐pPCK1‐pLDHA‐SPRINGlac axis as a novel mechanism driving ferroptosis resistance in AKT‐hyperactivated ICC by associating glycolytic activation with MVA flux reprogramming. Targeting this axis, potentially through statin‐based therapies, may offer a strategy to sensitize ICC cells to ferroptosis and improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisCholangiocarcinomaProto-Oncogene Proteins c-aktBile Duct NeoplasmsSimvastatinDrug Resistance, NeoplasmAnimalsHumansMiceCell Line, TumorMaleFemale

Stichwörter der Autor:innen

Chemo‐immunotherapyFerroptosisIntrahepatic cholangiocarcinomaLactylationMevalonate pathwayPCK1

Substanzen

Proto-Oncogene Proteins c-aktSimvastatin

Autor:innen und Institutionen

  • Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
  • Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei, P. R. China.
  • Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
  • Department of Gynecological Oncology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
  • Key Laboratory of Organ Transplantation, Ministry of Education, National Health Commission Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hu…
  • Department of Medical Oncology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P. R. China.

ORCID-Profile: Jinghan Zhu, Huifang Liang, Wanguang Zhang

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • China National Postdoctoral Program for Innovative Talents
  • Postdoctor Project of Hubei Province
  • Knowledge Innovation Program of Wuhan-Shuguang Project
  • Key Research and Development Program of Social Development of Jiangsu Province
  • Suzhou Science and Technology Development Plan Project
  • Jiangsu Province Seventh 333 High Level (Second Level) Talents Project

Zitieren

APA

Zhu, J., Xiong, Y., Zhang, Y., Liang, H., Cheng, K., Lu, Y., Cai, G., Wu, Y., Fan, Y., Chen, X., Zhu, H., Ding, Z., & Zhang, W. (2025). Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma. Cancer Communications, 45(8), 1038-1071. https://doi.org/10.1002/cac2.70036

Vancouver

Zhu J, Xiong Y, Zhang Y, Liang H, Cheng K, Lu Y, et al. Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma. Cancer Communications. 2025;45(8):1038-1071. doi:10.1002/cac2.70036

BibTeX
@article{Zhu2025,
  author = {Zhu, Jinghan and Xiong, Yixiao and Zhang, Yuxin and Liang, Huifang and Cheng, Kun and Lu, Yuanxiang and Cai, Guangzhen and Wu, Yang and Fan, Yunhui and Chen, Xiaoping and Zhu, Hong and Ding, Zeyang and Zhang, Wanguang},
  title = {Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {8},
  pages = {1038--1071},
  doi = {10.1002/cac2.70036}
}
Kostenlos starten →